540 related articles for article (PubMed ID: 26509843)
21. Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different.
Cheng AYY; Patel DK; Reid TS; Wyne K
Adv Ther; 2019 May; 36(5):1018-1030. PubMed ID: 30929185
[TBL] [Abstract][Full Text] [Related]
22. [Long-acting insulin analogs: progressing slowly].
Holleman F; Hoekstra JB
Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1668-9. PubMed ID: 15453117
[TBL] [Abstract][Full Text] [Related]
23. Higher concentration insulins: an overview of clinical considerations.
Reid TS; Schafer F; Brusko C
Postgrad Med; 2017 Jun; 129(5):554-562. PubMed ID: 28475455
[TBL] [Abstract][Full Text] [Related]
24. Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.
Kerlan V; Gouet D; Marre M; Renard É
Ann Endocrinol (Paris); 2013 Dec; 74(5-6):487-90. PubMed ID: 23978337
[TBL] [Abstract][Full Text] [Related]
25. Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs.
Poon K; King AB
Drug Healthc Patient Saf; 2010; 2():213-23. PubMed ID: 21701633
[TBL] [Abstract][Full Text] [Related]
26. The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?
Maiorino MI; Petrizzo M; Capuano A; Giugliano D; Esposito K
Expert Opin Biol Ther; 2014 Jun; 14(6):799-808. PubMed ID: 24673155
[TBL] [Abstract][Full Text] [Related]
27. Insulin preparations with prolonged effect.
Owens DR
Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S5-14. PubMed ID: 21668337
[TBL] [Abstract][Full Text] [Related]
28. Basal insulin therapy in type 2 diabetes.
Bethel MA; Feinglos MN
J Am Board Fam Pract; 2005; 18(3):199-204. PubMed ID: 15879567
[TBL] [Abstract][Full Text] [Related]
29. Evolution of insulin development: focus on key parameters.
Tibaldi JM
Adv Ther; 2012 Jul; 29(7):590-619. PubMed ID: 22843207
[TBL] [Abstract][Full Text] [Related]
30. New Insulins and New Aspects in Insulin Delivery.
Woo VC
Can J Diabetes; 2015 Aug; 39(4):335-43. PubMed ID: 26233724
[TBL] [Abstract][Full Text] [Related]
31. Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus.
Atkin S; Javed Z; Fulcher G
Ther Adv Chronic Dis; 2015 Nov; 6(6):375-88. PubMed ID: 26568812
[TBL] [Abstract][Full Text] [Related]
32. Introduction of biosimilar insulins in Europe.
Davies M; Dahl D; Heise T; Kiljanski J; Mathieu C
Diabet Med; 2017 Oct; 34(10):1340-1353. PubMed ID: 28608570
[TBL] [Abstract][Full Text] [Related]
33. Narrative review: a rational approach to starting insulin therapy.
Mooradian AD; Bernbaum M; Albert SG
Ann Intern Med; 2006 Jul; 145(2):125-34. PubMed ID: 16847295
[TBL] [Abstract][Full Text] [Related]
34. Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: advances in clinical research.
Muñoz Torres M
Endocrinol Nutr; 2014 Mar; 61(3):153-9. PubMed ID: 23890782
[TBL] [Abstract][Full Text] [Related]
35. New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin.
Frias PF; Frias JP
Curr Diab Rep; 2017 Aug; 17(10):91. PubMed ID: 28822051
[TBL] [Abstract][Full Text] [Related]
36. Insulin detemir: a new basal insulin analogue.
Soran H; Younis N
Diabetes Obes Metab; 2006 Jan; 8(1):26-30. PubMed ID: 16367879
[TBL] [Abstract][Full Text] [Related]
37. Long-acting insulin analogs versus human insulins.
Garg SK; Naik RG
Diabetes Technol Ther; 2008 Oct; 10(5):331-2. PubMed ID: 18715208
[No Abstract] [Full Text] [Related]
38. Gla-100 Development: a Story of 'Serendipitous' Disruptive Innovation.
Badgandi M; Negalur V; Reddy PS; Venkataraman S; Kota S; Barman KK; Jayaprassad V; Pasha MY; Sruthisri P; Mohan V
J Assoc Physicians India; 2020 Dec; 68(12[Special]):13-17. PubMed ID: 33247658
[TBL] [Abstract][Full Text] [Related]
39. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
Bode BW
Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety.
Rolla A
Am J Med; 2008 Jun; 121(6 Suppl):S9-S19. PubMed ID: 18514090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
